Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
International Journal of Cancer|August 22, 2024
Prolonged inhibition of intratumoral mast cells enhances efficacy of low-dose antiangiogenic therapyNikolaus Berenbrok, Maria Elena Vargas-Delgado, Antonia Beitzen-Heineke, et al.Oncotarget|April 8, 2015
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugsIsabel Ben-Batalla, Miguel Cubas-Cordova, Florian Udonta, et al.Cancer Research|April 21, 2018
Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic TherapyRaimund Bauer, Florian Udonta, Mark Wroblewski, et al.International Journal of Cancer|June 10, 2026
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS TrialJurek Hille, Sylvie Lorenzen, Claudia Pauligk, et al.Haematologica|March 24, 2018
BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cellsMark Wroblewski, Marina Scheller-Wendorff, Florian Udonta, et al.Hemasphere|August 16, 2021
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative NeoplasmsAntonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, et al.Nature Communications|December 12, 2022
Regulation of bone homeostasis by MERTK and TYRO3Janik Engelmann, Jennifer Zarrer, Victoria Gensch, et al.International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.Pageof 1